Kate Bechtold

Kate Bechtold, M.B.A. is Senior Director of Investor Relations and Communications for Vida Ventures.

Kate most recently served as Senior Director of Investor Relations for UroGen Pharma where she developed and implemented a strategic IR program from the ground up and also played a central role in the communications efforts for the approval and launch of Jelmyto™, (mitomycin) for pyelocalyceal solution, the first and only non-surgical treatment indicated for adults with low-grade upper tract urothelial cancer. Previously, Kate served as a key member of the Kite Pharma Investor Relations and Communications team in multiple roles, including Associate Director of Investor Relations and Associate Director of Product Communications, where she supported the approval and launch of Yescarta™ (axicabtagene ciloleucel), the first approved chimeric antigen receptor (CAR) T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin lymphoma. With an extensive healthcare background, Kate’s prior experience includes roles of increasing responsibility at Memorial Sloan Kettering Cancer Center in New York. She holds a B.A. from Cornell University College of Arts and Sciences and an M.B.A. from the University of Southern California Marshall School of Business.